STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more

Summary

GSK has acquired global rights to a multiple myeloma treatment developed in China as part of its pipeline expansion strategy. The article also mentions U.S. job losses but provides no additional details.